Matthew P Smeltzer1, Nicholas R Faris2, Meredith A Ray1, Raymond U Osarogiagbon2. 1. Division of Epidemiology, Biostatistics, and Environmental Health, School of Public Health, University of Memphis, Memphis, Tennessee. 2. Multidisciplinary Thoracic Oncology Program, Baptist Cancer Center, Memphis, Tennessee.
Abstract
IMPORTANCE: Pathologic nodal stage is the most significant prognostic factor in resectable non-small cell lung cancer (NSCLC). The International Association for the Study of Lung Cancer NSCLC staging project revealed intercontinental differences in N category-stratified survival. These differences may indicate differences not only in cancer biology but also in the thoroughness of the nodal examination. OBJECTIVE: To determine whether survival was affected by sequentially more stringent definitions of pN staging quality in a cohort of patients with NSCLC after resection with curative intent. DESIGN: This observational study used the Mid-South Quality of Surgical Resection cohort, a population-based database of lung cancer resections with curative intent. A total of 2047 consecutive patients who underwent surgical resection at 11 hospitals with at least 5 annual lung cancer resections in 4 contiguous US Dartmouth hospital referral regions in northern Mississippi, eastern Arkansas, and western Tennessee (>90% of the eligible population) were included. Resections were performed from January 1, 2009, through January 25, 2016. Survival was evaluated with the Kaplan-Meier method and Cox proportional hazards models. EXPOSURES: Eight sequentially more stringent pN staging quality strata included the following: all patients (group 1); those with complete resections only (group 2); those with examination of at least 1 mediastinal lymph node (group 3); those with examination of at least 10 lymph nodes (group 4); those with examination of at least 3 hilar or intrapulmonary and at least 3 mediastinal lymph nodes (group 5); those with examination of at least 10 lymph nodes, including at least 1 mediastinal lymph node (group 6); those with examination of at least 1 hilar or intrapulmonary and at least 3 mediastinal nodal stations (group 7); and those with examination of at least 1 hilar or intrapulmonary lymph node, at least 10 total lymph nodes, and at least 3 mediastinal nodal stations (group 8). MAIN OUTCOMES AND MEASURES: N category-stratified overall survival. RESULTS: Of the total 2047 patients (1046 men [51.1%] and 1001 women [48.9%]; mean [SD] age, 67.0 [9.6] years) included in the analysis, the eligible analysis population ranged from 541 to 2047, depending on stringency. Sequential improvement in the N category-stratified 5-year survival of pN0 and pN1 tumors was found from the least stringent group (0.63 [95% CI, 0.59-0.66] for pN0 vs 0.46 [95% CI, 0.38-0.54] for pN1) to the most stringent group (0.71 [95% CI, 0.60-0.79] for pN0 vs 0.60 [95% CI, 0.43-0.73] for pN1). The pN1 cohorts with 3 or more mediastinal nodal stations examined had the most striking survival improvements. More stringently defined mediastinal nodal examination was associated with better separation in survival curves between patients with pN1 and pN2 tumors. CONCLUSIONS AND RELEVANCE: The prognostic value of pN stratification depends on the thoroughness of examination. Differences in thoroughness of nodal staging may explain a large proportion of intercontinental survival differences. More thorough nodal examination practice must be disseminated to improve the prognostic value of the TNM staging system. Future updates of the TNM staging system should incorporate more quality restraints.
IMPORTANCE: Pathologic nodal stage is the most significant prognostic factor in resectable non-small cell lung cancer (NSCLC). The International Association for the Study of Lung Cancer NSCLC staging project revealed intercontinental differences in N category-stratified survival. These differences may indicate differences not only in cancer biology but also in the thoroughness of the nodal examination. OBJECTIVE: To determine whether survival was affected by sequentially more stringent definitions of pN staging quality in a cohort of patients with NSCLC after resection with curative intent. DESIGN: This observational study used the Mid-South Quality of Surgical Resection cohort, a population-based database of lung cancer resections with curative intent. A total of 2047 consecutive patients who underwent surgical resection at 11 hospitals with at least 5 annual lung cancer resections in 4 contiguous US Dartmouth hospital referral regions in northern Mississippi, eastern Arkansas, and western Tennessee (>90% of the eligible population) were included. Resections were performed from January 1, 2009, through January 25, 2016. Survival was evaluated with the Kaplan-Meier method and Cox proportional hazards models. EXPOSURES: Eight sequentially more stringent pN staging quality strata included the following: all patients (group 1); those with complete resections only (group 2); those with examination of at least 1 mediastinal lymph node (group 3); those with examination of at least 10 lymph nodes (group 4); those with examination of at least 3 hilar or intrapulmonary and at least 3 mediastinal lymph nodes (group 5); those with examination of at least 10 lymph nodes, including at least 1 mediastinal lymph node (group 6); those with examination of at least 1 hilar or intrapulmonary and at least 3 mediastinal nodal stations (group 7); and those with examination of at least 1 hilar or intrapulmonary lymph node, at least 10 total lymph nodes, and at least 3 mediastinal nodal stations (group 8). MAIN OUTCOMES AND MEASURES: N category-stratified overall survival. RESULTS: Of the total 2047 patients (1046 men [51.1%] and 1001 women [48.9%]; mean [SD] age, 67.0 [9.6] years) included in the analysis, the eligible analysis population ranged from 541 to 2047, depending on stringency. Sequential improvement in the N category-stratified 5-year survival of pN0 and pN1 tumors was found from the least stringent group (0.63 [95% CI, 0.59-0.66] for pN0 vs 0.46 [95% CI, 0.38-0.54] for pN1) to the most stringent group (0.71 [95% CI, 0.60-0.79] for pN0 vs 0.60 [95% CI, 0.43-0.73] for pN1). The pN1 cohorts with 3 or more mediastinal nodal stations examined had the most striking survival improvements. More stringently defined mediastinal nodal examination was associated with better separation in survival curves between patients with pN1 and pN2 tumors. CONCLUSIONS AND RELEVANCE: The prognostic value of pN stratification depends on the thoroughness of examination. Differences in thoroughness of nodal staging may explain a large proportion of intercontinental survival differences. More thorough nodal examination practice must be disseminated to improve the prognostic value of the TNM staging system. Future updates of the TNM staging system should incorporate more quality restraints.
Authors: Robert A Ramirez; Christopher G Wang; Laura E Miller; Courtney A Adair; Allen Berry; Xinhua Yu; Thomas F O'Brien; Raymond U Osarogiagbon Journal: J Clin Oncol Date: 2012-07-09 Impact factor: 44.544
Authors: Raymond U Osarogiagbon; Matthew P Smeltzer; Nicholas Faris; Ramón Rami-Porta; Peter Goldstraw; Hisao Asamura Journal: J Thorac Oncol Date: 2016-10 Impact factor: 15.609
Authors: Gail E Darling; Mark S Allen; Paul A Decker; Karla Ballman; Richard A Malthaner; Richard I Inculet; David R Jones; Robert J McKenna; Rodney J Landreneau; Valerie W Rusch; Joe B Putnam Journal: J Thorac Cardiovasc Surg Date: 2011-03 Impact factor: 5.209
Authors: Matthew P Smeltzer; Nicholas Faris; Xinhua Yu; Robert A Ramirez; Laura E M Ramirez; Christopher G Wang; Courtney Adair; Allen Berry; Raymond U Osarogiagbon Journal: Ann Thorac Surg Date: 2016-06-03 Impact factor: 4.330
Authors: Raymond U Osarogiagbon; Paul A Decker; Karla Ballman; Dennis Wigle; Mark S Allen; Gail E Darling Journal: Ann Thorac Surg Date: 2016-06-02 Impact factor: 4.330
Authors: Hisao Asamura; Kari Chansky; John Crowley; Peter Goldstraw; Valerie W Rusch; Johan F Vansteenkiste; Hirokazu Watanabe; Yi-Long Wu; Marcin Zielinski; David Ball; Ramon Rami-Porta Journal: J Thorac Oncol Date: 2015-12 Impact factor: 15.609
Authors: Farhood Farjah; David R Flum; Scott D Ramsey; Patrick J Heagerty; Rebecca Gaston Symons; Douglas E Wood Journal: J Thorac Oncol Date: 2009-03 Impact factor: 15.609
Authors: Eric M Robinson; Ilkka K Ilonen; Kay See Tan; Andrew J Plodkowski; Matthew Bott; Manjit S Bains; Prasad S Adusumilli; Bernard J Park; Valerie W Rusch; David R Jones; James Huang Journal: Ann Thorac Surg Date: 2019-08-31 Impact factor: 4.330
Authors: Raymond U Osarogiagbon; Nicholas R Faris; Walter Stevens; Carrie Fehnel; Cheryl Houston-Harris; Philip Ojeabulu; Olawale A Akinbobola; Yu-Shen Lee; Meredith A Ray; Matthew P Smeltzer Journal: J Thorac Oncol Date: 2019-11-26 Impact factor: 15.609
Authors: Matthew P Smeltzer; Nicholas R Faris; Meredith A Ray; Carrie Fehnel; Cheryl Houston-Harris; Philip Ojeabulu; Olawale Akinbobola; Yu-Sheng Lee; Meghan Meadows; R Samuel Signore; Lynn Wiggins; David Talton; Edmond Owen; Lawrence E Deese; Richard Eubanks; Bradley A Wolf; Paul Levy; E Todd Robbins; Raymond U Osarogiagbon Journal: Ann Thorac Surg Date: 2018-12-27 Impact factor: 4.330
Authors: Raymond U Osarogiagbon; Matthew P Smeltzer; Nicholas R Faris; Meredith A Ray; Carrie Fehnel; Phillip Ojeabulu; Olawale Akinbobola; Meghan Meadows-Taylor; Laura M McHugh; Ahmed M Halal; Paul Levy; Vishal Sachdev; David Talton; Lynn Wiggins; Xiao-Ou Shu; Yu Shyr; Edward T Robbins; Lisa M Klesges Journal: J Thorac Oncol Date: 2021-02-16 Impact factor: 15.609
Authors: Meredith A Ray; Carrie Fehnel; Olawale Akinbobola; Nicholas R Faris; Meghan Taylor; Alicia Pacheco; Matthew P Smeltzer; Raymond U Osarogiagbon Journal: J Thorac Oncol Date: 2021-02-12 Impact factor: 15.609
Authors: Megan E V Caram; Mary K Oerline; Stacie Dusetzina; Lindsey A Herrel; Parth K Modi; Samuel R Kaufman; Ted A Skolarus; Brent K Hollenbeck; Vahakn Shahinian Journal: Cancer Date: 2020-09-14 Impact factor: 6.860